Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
The Effect of Ethinylestradiol (EE)/Cyproterone Acetate (CA) and EE/CA Plus Metformin Treatment on Adhesion Molecules in Cases with Polycystic Ovary Syndrome (PCOS)
Oktay BilgirLevent KebapcilarCuneyt TanerFerda BilgirAyse KebapcilarGiray BozkayaYasar YildizArif YukselIsmail Sari
Author information

2009 Volume 48 Issue 14 Pages 1193-1199


Objective To determine if EE/CA and EE/CA plus metformin treatment have any effect on adhesion molecules in cases with PCOS.
Methods Among 40 patients diagnosed with PCOS, one study arm was administered EE/CA (n=20, cyproterone acetate 2 mg, ethinylestradiol 35 μg) and the other was administered metformin (1,700 mg) combined with EE/CA (n=20, cyproterone acetate 2 mg, ethinylestradiol 35 μg). Soluble intercellular adhesion molecule-1 (sICAM-1), soluble endothelial leukocyte adhesion molecule-1 (sE-selectin), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble leukocyte endothelial cell adhesion molecule-3 (sP-selectin), lipid profile, androgens, insulin, and HOMA-IR values were assessed prior to treatment and after 3 months of therapy.
Results The comparison of the groups receiving EE/CA and EE/CA+metformin revealed a significant reduction in sVCAM (1,445±614 vs 1,167±482, p<0.05) and sICAM (442±141 vs 345±118, p<0.05) values relative to pre-treatment values while no significant changes were detected in sE-selectin and sP-selectin levels relative to pre-treatment levels in the EE/CA+metformin group (p>0.05). In the post-treatment period, sVCAM, sICAM, sE-selectin values did not significantly change compared to the pre-treatment values in EE/CA group (p>0.05). sP-selectin levels were also decreased but missed the significance in EE/CA group (229.4±68.0 vs 189.6±65.0, p=0.08).
Conclusion These results demonstrate that EE/CA+metformin treatment reduced inflammation markers in cases with PCOS compared to EE/CA treatment. The clinical relevance of this conclusion may be clarified by longer metformin treatment and clinical follow-up.

Content from these authors
© 2009 by The Japanese Society of Internal Medicine
Next article